Condition

Leptomeningeal Metastasis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 39 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials39

Recruiting13

Common interventions25

Lead sponsors shown15

Clinical trials

39 shown

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisNCT07348965 · 2026-03-01

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyNCT07398599 · 2026-02-15

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.NCT06296745 · 2025-09-01

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal MetastasesNCT06901817 · 2025-03-01

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisNCT06643000 · 2024-12-20

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCNCT06663306 · 2024-12-09

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLCNCT05805631 · 2024-08-01

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerNCT06431685 · 2024-04-25

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerNCT06304441 · 2024-04-18

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal MetastasisNCT06230055 · 2024-01-05

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseNCT05800275 · 2023-12-18

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya ReservoirNCT06399926 · 2023-10-30

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal DiseaseNCT05257967 · 2022-07-18

BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor MalignanciesNCT07789912 · 2026-10-01

NOT_YET_RECRUITING

Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.NCT07778940 · 2026-09-01

NOT_YET_RECRUITING

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKINCT07551414 · 2026-05-30

NOT_YET_RECRUITING

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNCT07177950 · 2025-09-30

NOT_YET_RECRUITING

AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center StudyNCT07005791 · 2025-07-01

NOT_YET_RECRUITING

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesNCT06282874 · 2024-08-01

ACTIVE_NOT_RECRUITING

Intrathecal Double Checkpoint InhibitionNCT05598853 · 2022-11-25

ACTIVE_NOT_RECRUITING

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSideNCT05414123 · 2022-09-07

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)NCT04315246 · 2022-08-31

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung CancerNCT05385185 · 2022-05-01

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationNCT05146219 · 2022-04-02

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisNCT04944069 · 2021-07-01

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung CancerNCT04833205 · 2021-04-19

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)NCT04778800 · 2021-03-20

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseNCT04588545 · 2020-12-10

ACTIVE_NOT_RECRUITING

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationNCT04233021 · 2020-07-16

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisNCT04356118 · 2020-06-01

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisNCT04356222 · 2020-06-01

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] DiseaseNCT04420598 · 2020-05-25

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System MetastasisNCT07239102 · 2020-01-01

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisNCT04148898 · 2019-11-01

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.NCT03974204 · 2019-07-01

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerNCT04425681 · 2017-10-01

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast CancerNCT02948751 · 2017-02-06

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal MetastasisNCT02803619 · 2013-11-01

Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal MetastasisNCT01281696 · 2011-01-01

Common interventions

PemetrexedDRUG6 BevacizumabDRUG4 OsimertinibDRUG4 almonertinibDRUG2 a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patientsCOMBINATION_PRODUCT1 Bevacizumab, etoposide, cisplatinDRUG1 Camrelizumab or envafolimabDRUG1 Capecitabine tabletsDRUG1 Cerebrospinal fluid and blood sample collection at the initial diagnostic assessmentPROCEDURE1 Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "confirmed", "probable" or "possible", leading to leptomeningeal metastase specific treatmentPROCEDURE1 Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "Lack of evidence" according to EANO-ESMO classificationPROCEDURE1 ChemotherapyDRUG1 CNSideDEVICE1 DurvalumabDRUG1 FirmonertinibDRUG1 furmonertinibDRUG1 Furmonertinib 160mg qd poDRUG1 Furmonertinib 320mg qod poDRUG1 intrathcal methotrexateDRUG1 Intrathecal chemotherapyDRUG1 Intrathecal methotrexateDRUG1 intrathecal nivolumab and intrathecal ipilimumabDRUG1 Intraventricular DexamethasoneDRUG1 Intraventricular NivolumabDRUG1 Intraventricular PemetrexedDRUG1

Leading sponsors

Second Affiliated Hospital of Nanchang University 4 Hui Bu 3 Guangzhou Medical University 2 Henan Cancer Hospital 2 Beijing Tiantan Hospital 1 Biocept, Inc. 1 British Columbia Cancer Agency 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 Centre Oscar Lambret 1 Columbia University 1 Fudan University 1 Guangdong Association of Clinical Trials 1 Guangzhou University of Traditional Chinese Medicine 1 H. Lee Moffitt Cancer Center and Research Institute 1 Hebei Medical University 1

Trial status mix

RECRUITING13

UNKNOWN9

COMPLETED6

NOT_YET_RECRUITING5

ACTIVE_NOT_RECRUITING3

WITHDRAWN2

TERMINATED1

Phase mix

PHASE218

NA8

PHASE16

PHASE44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.